BioCentury | Nov 30, 2018
Company News

Alvotech grants Fuji rights to biosimilar portfolio in Japan

...Alvotech ehf (Reykjavik, Iceland) granted Fuji Pharma Co. Ltd. (Tokyo:4554) exclusive rights to commercialize Alvotech's biosimilar...
...biosimilar portfolio in Japan. Fuji will be responsible for registration and commercialization of the biosimilars. Alvotech...
...respond to inquiries. Alvotech ehf, Reykjavik, Iceland Fuji Pharma Co. Ltd. (Tokyo:4554), Tokyo, Japan Business: Biosimilars Shannon Lehnbeuter Alvotech ehf Fuji...
BioCentury | Aug 7, 2017
Company News

Management tracks: Pfenex, Alvotech, uniQure

...Patrick Lucy, who will continue as CBO. Rasmus Rojkjaer was named CEO at biosimilar company Alvotech ehf...
BioCentury | Dec 16, 2013
Company News

Alvogen, Alvotech biosimilars news

...Alvogen and undisclosed external investors will invest $250 million in Alvotech, which will use the money...
...money to develop and manufacture a portfolio of undisclosed biosimilar mAbs for the global market. Alvotech...
...by Alvogen, which created Alvotech earlier this year to develop and manufacture Alvogen's biosimilars platform. Alvotech...
Items per page:
1 - 3 of 3
BioCentury | Nov 30, 2018
Company News

Alvotech grants Fuji rights to biosimilar portfolio in Japan

...Alvotech ehf (Reykjavik, Iceland) granted Fuji Pharma Co. Ltd. (Tokyo:4554) exclusive rights to commercialize Alvotech's biosimilar...
...biosimilar portfolio in Japan. Fuji will be responsible for registration and commercialization of the biosimilars. Alvotech...
...respond to inquiries. Alvotech ehf, Reykjavik, Iceland Fuji Pharma Co. Ltd. (Tokyo:4554), Tokyo, Japan Business: Biosimilars Shannon Lehnbeuter Alvotech ehf Fuji...
BioCentury | Aug 7, 2017
Company News

Management tracks: Pfenex, Alvotech, uniQure

...Patrick Lucy, who will continue as CBO. Rasmus Rojkjaer was named CEO at biosimilar company Alvotech ehf...
BioCentury | Dec 16, 2013
Company News

Alvogen, Alvotech biosimilars news

...Alvogen and undisclosed external investors will invest $250 million in Alvotech, which will use the money...
...money to develop and manufacture a portfolio of undisclosed biosimilar mAbs for the global market. Alvotech...
...by Alvogen, which created Alvotech earlier this year to develop and manufacture Alvogen's biosimilars platform. Alvotech...
Items per page:
1 - 3 of 3